Table 1.
Demographic characteristics of the study cohort and the reactogenicity cohort
| Characteristic at vaccination | Study cohort (N=9143) | Reactogenicity cohort (N=682) |
|---|---|---|
| Age (years) | ||
| Mean±SD | 54.7±20.22 | 47.5±24.27 |
| Median (min–max) | 60.0 (0–97) | 54.0 (0–88) |
| Age groups (years) | n (%) | n (%) |
| <2* | 34 (0.4) | 14 (2.1) |
| 2–4 | 134 (1.5) | 47 (6.9) |
| 5–9 | 182 (2.0) | 31 (4.5) |
| 10–17 | 319 (3.5) | 35 (5.1) |
| 18–44 | 1717 (18.8) | 125 (18.3) |
| 45–60 | 2391 (26.2) | 168 (24.6) |
| >60 | 4365 (47.7) | 262 (38.4) |
| Gender | n (%) | n (%) |
| Female | 4672 (51.1) | 360 (52.8) |
| Male | 4471 (48.9) | 322 (47.2) |
| Risk group† | n (%) | n (%) |
| Healthy | 1170 (12.8) | 117 (17.2) |
| Immunocompromised | 579 (6.3) | 39 (5.7) |
| Non-immunocompromised and At-risk | 7392 (80.9) | 526 (77.1) |
*The <2 years age group included participants 7−23 months of age.
†Information regarding the risk group was missing for two participants in the Study cohort.
Max, maximum; min, minimum; N, number of participants in the cohort; n (%), number (percentage) of participants in the category; SD, standard deviation.